Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Rimantadine Articles

Canada adjusts pandemic drug stockpile mix over resistance fear

22 April 2009

Research points to new therapy for HCV

15 December 2008

UK's bird flu vacc stocks "should rise 600%"

19 February 2007

US FDA prohibits poultry antivirals

27 March 2006

Amantadine finds new role as Tamiflu adjunct

20 March 2006

Forest disappoints, despite 17% EPS hike

24 January 2005

US Medicare announces demonstration to pay for flu antiviral drugs

17 January 2005

US HHS Sec seeks to assure on flu vaccine

1 November 2004

First human efficacy data with J&J's oral neuraminidase candidate

20 September 2000

BioCryst boosted as J&J-partnered flu drug enters Phase III - update

9 February 2000

Influenza drugs battle for supremacy, new prophylaxis data

29 September 1999

New Drugs, Vaccine Shift Balance In War Against Flu

30 September 1998

Gilead's Oral Flu Drug Nears Trials

3 February 1997

Antivirals "Now 9% Of Anti-Infectives Market"

11 March 1996

1ST QUARTER RESULTS VARY FOR US FIRMS

23 May 1994

NEW YORK STOCK COMMENT

1 November 1993

FOREST'S FLUMADINE APPROVED FOR FLU

27 September 1993

FOREST LABS IN MERCK & CO DEAL

3 August 1992

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS